Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Gains from Investment Securities (2020 - 2025)

Pulse Biosciences (PLSE) has 6 years of Gains from Investment Securities data on record, last reported at -$14000.0 in Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 101.69% year-over-year to -$14000.0; the TTM value through Dec 2025 reached $817000.0, up 36.62%, while the annual FY2025 figure was $14000.0, 99.87% down from the prior year.
  • Gains from Investment Securities reached -$14000.0 in Q4 2025 per PLSE's latest filing, down from $1000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.1 million in Q4 2023 and bottomed at -$232000.0 in Q4 2021.
  • Average Gains from Investment Securities over 5 years is $1.3 million, with a median of $708611.0 recorded in 2022.
  • Peak YoY movement for Gains from Investment Securities: crashed 2220.0% in 2021, then skyrocketed 56225.2% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at -$232000.0 in 2021, then skyrocketed by 2138.96% to $4.7 million in 2022, then increased by 29.84% to $6.1 million in 2023, then plummeted by 86.49% to $830000.0 in 2024, then tumbled by 101.69% to -$14000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$14000.0 in Q4 2025, $1000.0 in Q1 2025, and $830000.0 in Q4 2024.